|
SNDX | Syndax Pharmaceuticals Inc |
|
|
SNDX | Syndax Pharmaceuticals Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.62 |
| Leverage | 62.14% |
| Market Cap | $ 1.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -330.2m |
| Margin | -856.14% |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.